Baseline characteristics of the study populations
| . | Control (n = 53) . | CGM (n = 105) . | P value . |
|---|---|---|---|
| Demographic characteristics | |||
| Female sex, n (%) | 23 (43) | 47 (45) | 1 |
| Race, n (%) | 0.5 | ||
| White | 50 (94) | 95 (90) | |
| Black | 3 (6) | 6 (6) | |
| Other | 0 (0) | 4 (4) | |
| Age (years) | <0.01 | ||
| Mean ± SD | 51.4 ± 10.9 | 45.7 ± 13.6 | |
| Range | 25–73 | 25–72 | |
| T1D duration (years) | 0.1 | ||
| Mean ± SD | 23.1 ± 14.5 | 19.6 ± 13.1 | |
| Range | 4–56 | 2–56 | |
| Clinical outcomes at baseline | |||
| HbA1c (%) | 0.6 | ||
| Mean ± SD | 8.6 ± 0.6 | 8.6 ± 0.7 | |
| Range | 7.5–9.9 | 7.5–9.9 | |
| Daily strip tests (n) | 0.4 | ||
| Mean ± SD | 4.1 ± 1.6 | 3.9 ± 1.3 | |
| Range | 1–9 | 1–7 | |
| Insulin (units) | 0.4 | ||
| Mean ± SD | 60.2 ± 32.7 | 66.0 ± 36.7 | |
| Range | 12–185 | 24–155 | |
| Daily event rate of NSHEs | 0.5 | ||
| Mean ± SD | 0.35 ± 0.33 | 0.30 ± 0.29 | |
| Range | 0–1.34 | 1–1.33 | |
| Utility | 0.6 | ||
| Mean ± SD | 0.91 ± 0.13 | 0.93 ± 0.10 | |
| Range | 0.26–1.0 | 0.38–1.0 | |
| BMI (kg/m2) | 0.2 | ||
| Mean ± SD | 26.8 ± 4.6 | 27.9 ± 5.9 | |
| Range | 18.2–38.4 | 16.9–62.6 | |
| Patients using noninsulin glucose–lowering medication, n (%) | 8 (8) | 4 (8) | 1.0 |
| Patients having severe hypoglycemia in previous 12 months, n (%) | 8 (8) | 9 (17) | 0.1 |
| Patients having severe hyperglycemia in previous 12 months, n (%) | 1 (2) | 1 (<1) | 1.0 |
| . | Control (n = 53) . | CGM (n = 105) . | P value . |
|---|---|---|---|
| Demographic characteristics | |||
| Female sex, n (%) | 23 (43) | 47 (45) | 1 |
| Race, n (%) | 0.5 | ||
| White | 50 (94) | 95 (90) | |
| Black | 3 (6) | 6 (6) | |
| Other | 0 (0) | 4 (4) | |
| Age (years) | <0.01 | ||
| Mean ± SD | 51.4 ± 10.9 | 45.7 ± 13.6 | |
| Range | 25–73 | 25–72 | |
| T1D duration (years) | 0.1 | ||
| Mean ± SD | 23.1 ± 14.5 | 19.6 ± 13.1 | |
| Range | 4–56 | 2–56 | |
| Clinical outcomes at baseline | |||
| HbA1c (%) | 0.6 | ||
| Mean ± SD | 8.6 ± 0.6 | 8.6 ± 0.7 | |
| Range | 7.5–9.9 | 7.5–9.9 | |
| Daily strip tests (n) | 0.4 | ||
| Mean ± SD | 4.1 ± 1.6 | 3.9 ± 1.3 | |
| Range | 1–9 | 1–7 | |
| Insulin (units) | 0.4 | ||
| Mean ± SD | 60.2 ± 32.7 | 66.0 ± 36.7 | |
| Range | 12–185 | 24–155 | |
| Daily event rate of NSHEs | 0.5 | ||
| Mean ± SD | 0.35 ± 0.33 | 0.30 ± 0.29 | |
| Range | 0–1.34 | 1–1.33 | |
| Utility | 0.6 | ||
| Mean ± SD | 0.91 ± 0.13 | 0.93 ± 0.10 | |
| Range | 0.26–1.0 | 0.38–1.0 | |
| BMI (kg/m2) | 0.2 | ||
| Mean ± SD | 26.8 ± 4.6 | 27.9 ± 5.9 | |
| Range | 18.2–38.4 | 16.9–62.6 | |
| Patients using noninsulin glucose–lowering medication, n (%) | 8 (8) | 4 (8) | 1.0 |
| Patients having severe hypoglycemia in previous 12 months, n (%) | 8 (8) | 9 (17) | 0.1 |
| Patients having severe hyperglycemia in previous 12 months, n (%) | 1 (2) | 1 (<1) | 1.0 |